Literature DB >> 18676840

Reciprocal relationship between O6-methylguanine-DNA methyltransferase P140K expression level and chemoprotection of hematopoietic stem cells.

Michael D Milsom1, Moran Jerabek-Willemsen, Chad E Harris, Axel Schambach, Emily Broun, Jeff Bailey, Michael Jansen, David Schleimer, Kalpana Nattamai, Jamie Wilhelm, Amanda Watson, Hartmut Geiger, Geoffrey P Margison, Thomas Moritz, Christopher Baum, Jürgen Thomale, David A Williams.   

Abstract

Retroviral-mediated delivery of the P140K mutant O(6)-methylguanine-DNA methyltransferase (MGMT(P140K)) into hematopoietic stem cells (HSC) has been proposed as a means to protect against dose-limiting myelosuppressive toxicity ensuing from chemotherapy combining O(6)-alkylating agents (e.g., temozolomide) with pseudosubstrate inhibitors (such as O(6)-benzylguanine) of endogenous MGMT. Because detoxification of O(6)-alkylguanine adducts by MGMT is stoichiometric, it has been suggested that higher levels of MGMT will afford better protection to gene-modified HSC. However, accomplishing this goal would potentially be in conflict with current efforts in the gene therapy field, which aim to incorporate weaker enhancer elements to avoid insertional mutagenesis. Using a panel of self-inactivating gamma-retroviral vectors that express a range of MGMT(P140K) activity, we show that MGMT(P140K) expression by weaker cellular promoter/enhancers is sufficient for in vivo protection/selection following treatment with O(6)-benzylguanine/temozolomide. Conversely, the highest level of MGMT(P140K) activity did not promote efficient in vivo protection despite mediating detoxification of O(6)-alkylguanine adducts. Moreover, very high expression of MGMT(P140K) was associated with a competitive repopulation defect in HSC. Mechanistically, we show a defect in cellular proliferation associated with elevated expression of MGMT(P140K), but not wild-type MGMT. This proliferation defect correlated with increased localization of MGMT(P140K) to the nucleus/chromatin. These data show that very high expression of MGMT(P140K) has a deleterious effect on cellular proliferation, engraftment, and chemoprotection. These studies have direct translational relevance to ongoing clinical gene therapy studies using MGMT(P140K), whereas the novel mechanistic findings are relevant to the basic understanding of DNA repair by MGMT.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18676840      PMCID: PMC4337843          DOI: 10.1158/0008-5472.CAN-08-0320

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  38 in total

1.  O6-alkylguanine-DNA alkyltransferase assay.

Authors:  A J Watson; G P Margison
Journal:  Methods Mol Biol       Date:  2000

2.  Implication of localization of human DNA repair enzyme O6-methylguanine-DNA methyltransferase at active transcription sites in transcription-repair coupling of the mutagenic O6-methylguanine lesion.

Authors:  R B Ali; A K Teo; H K Oh; L S Chuang; T C Ayi; B F Li
Journal:  Mol Cell Biol       Date:  1998-03       Impact factor: 4.272

3.  Protection and in vivo selection of hematopoietic stem cells using temozolomide, O6-benzylguanine, and an alkyltransferase-expressing retroviral vector.

Authors:  N Sawai; S Zhou; E F Vanin; P Houghton; T P Brent; B P Sorrentino
Journal:  Mol Ther       Date:  2001-01       Impact factor: 11.454

4.  Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity.

Authors:  Ute Modlich; Jens Bohne; Manfred Schmidt; Christof von Kalle; Sabine Knöss; Axel Schambach; Christopher Baum
Journal:  Blood       Date:  2006-07-06       Impact factor: 22.113

5.  Modulation of mammalian O6-alkylguanine-DNA alkyltransferase in vivo by O6-benzylguanine and its effect on the sensitivity of a human glioma tumor to 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea.

Authors:  M E Dolan; L Stine; R B Mitchell; R C Moschel; A E Pegg
Journal:  Cancer Commun       Date:  1990

6.  Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.

Authors:  H S Friedman; J Pluda; J A Quinn; R B Ewesuedo; L Long; A H Friedman; I Cokgor; O M Colvin; M M Haglund; D M Ashley; J N Rich; J Sampson; A E Pegg; R C Moschel; R E McLendon; J M Provenzale; E S Stewart; S Tourt-Uhlig; A M Garcia-Turner; J E Herndon; D D Bigner; M E Dolan
Journal:  J Clin Oncol       Date:  2000-10-15       Impact factor: 44.544

7.  Down-regulation of DNA repair in human CD34(+) progenitor cells corresponds to increased drug sensitivity and apoptotic response.

Authors:  Claudia Buschfort-Papewalis; Thomas Moritz; Bernd Liedert; Jürgen Thomale
Journal:  Blood       Date:  2002-08-01       Impact factor: 22.113

8.  O6 alkylguanine-DNA alkyltransferase activity in human myeloid cells.

Authors:  S L Gerson; K Miller; N A Berger
Journal:  J Clin Invest       Date:  1985-12       Impact factor: 14.808

9.  Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study.

Authors:  K A Jaeckle; H J Eyre; J J Townsend; S Schulman; H M Knudson; M Belanich; D B Yarosh; S I Bearman; D J Giroux; S C Schold
Journal:  J Clin Oncol       Date:  1998-10       Impact factor: 44.544

10.  Intensive 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), NSC #4366650 and cryopreserved autologous marrow transplantation for refractory cancer. A phase I-II study.

Authors:  G L Phillips; J W Fay; G P Herzig; R H Herzig; R S Weiner; S N Wolff; H M Lazarus; C Karanes; W E Ross; B S Kramer
Journal:  Cancer       Date:  1983-11-15       Impact factor: 6.860

View more
  11 in total

1.  Repair of O4-alkylthymine by O6-alkylguanine-DNA alkyltransferases.

Authors:  Qingming Fang; Sreenivas Kanugula; Julie L Tubbs; John A Tainer; Anthony E Pegg
Journal:  J Biol Chem       Date:  2009-12-21       Impact factor: 5.157

2.  Foamy viral vector integration sites in SCID-repopulating cells after MGMTP140K-mediated in vivo selection.

Authors:  M E Olszko; J E Adair; I Linde; D T Rae; P Trobridge; J D Hocum; D J Rawlings; H-P Kiem; G D Trobridge
Journal:  Gene Ther       Date:  2015-03-19       Impact factor: 5.250

3.  Tightly regulated 'all-in-one' lentiviral vectors for protection of human hematopoietic cells from anticancer chemotherapy.

Authors:  N Lachmann; S Brennig; R Hillje; H Schermeier; R Phaltane; J Dahlmann; I Gruh; N Heinz; B Schiedlmeier; C Baum; T Moritz
Journal:  Gene Ther       Date:  2015-06-30       Impact factor: 5.250

Review 4.  Multifaceted roles of alkyltransferase and related proteins in DNA repair, DNA damage, resistance to chemotherapy, and research tools.

Authors:  Anthony E Pegg
Journal:  Chem Res Toxicol       Date:  2011-04-28       Impact factor: 3.739

5.  Correction of murine β-thalassemia after minimal lentiviral gene transfer and homeostatic in vivo erythroid expansion.

Authors:  Olivier Negre; Floriane Fusil; Charlotte Colomb; Shoshannah Roth; Beatrix Gillet-Legrand; Annie Henri; Yves Beuzard; Frederic Bushman; Philippe Leboulch; Emmanuel Payen
Journal:  Blood       Date:  2011-03-24       Impact factor: 22.113

6.  Efficiency and safety of O⁶-methylguanine DNA methyltransferase (MGMT(P140K))-mediated in vivo selection in a humanized mouse model.

Authors:  Ruhi Phaltane; Reinhard Haemmerle; Michael Rothe; Ute Modlich; Thomas Moritz
Journal:  Hum Gene Ther       Date:  2014-01-07       Impact factor: 5.695

7.  Ectopic HOXB4 overcomes the inhibitory effect of tumor necrosis factor-{alpha} on Fanconi anemia hematopoietic stem and progenitor cells.

Authors:  Michael D Milsom; Bernhard Schiedlmeier; Jeff Bailey; Mi-Ok Kim; Dandan Li; Michael Jansen; Abdullah Mahmood Ali; Michelle Kirby; Christopher Baum; Leslie J Fairbairn; David A Williams
Journal:  Blood       Date:  2009-03-06       Impact factor: 22.113

8.  In vivo selection of hematopoietic progenitor cells and temozolomide dose intensification in rhesus macaques through lentiviral transduction with a drug resistance gene.

Authors:  Andre Larochelle; Uimook Choi; Yan Shou; Nora Naumann; Natalia A Loktionova; Joshua R Clevenger; Allen Krouse; Mark Metzger; Robert E Donahue; Elizabeth Kang; Clinton Stewart; Derek Persons; Harry L Malech; Cynthia E Dunbar; Brian P Sorrentino
Journal:  J Clin Invest       Date:  2009-06-08       Impact factor: 14.808

9.  Amelioration of murine beta-thalassemia through drug selection of hematopoietic stem cells transduced with a lentiviral vector encoding both gamma-globin and the MGMT drug-resistance gene.

Authors:  Huifen Zhao; Tamara I Pestina; Md Nasimuzzaman; Perdeep Mehta; Phillip W Hargrove; Derek A Persons
Journal:  Blood       Date:  2009-04-13       Impact factor: 22.113

10.  Long-term polyclonal and multilineage engraftment of methylguanine methyltransferase P140K gene-modified dog hematopoietic cells in primary and secondary recipients.

Authors:  Brian C Beard; Reeteka Sud; Kirsten A Keyser; Christina Ironside; Tobias Neff; Sabine Gerull; Grant D Trobridge; Hans-Peter Kiem
Journal:  Blood       Date:  2009-03-31       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.